• Calidi Biotherapeutics presented new preclinical data on its CLD-401 cancer program at the AACR Drug Discovery and Development Conference on July 23, 2026.
• The update indicated tumor-cell killing activity in human and mouse models, supporting the program’s development rationale without disclosing detailed performance measures.
• Calidi reiterated expectations to enter CLD-401 into the clinic in Q1 2027, setting a near-term milestone for the RedTail platform.
• New findings also covered an in situ T-cell engager approach, including a candidate targeting EpCam, extending the platform’s product scope.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788249) on July 27, 2026, and is solely responsible for the information contained therein.